AAV vector

1 stories · following the connections

Business

Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic

By Nasdaq OMXApr 25, 2018, 12:05 PM UTC